1. Home
  2. FCN vs COGT Comparison

FCN vs COGT Comparison

Compare FCN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FTI Consulting Inc.

FCN

FTI Consulting Inc.

HOLD

Current Price

$174.90

Market Cap

5.0B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$32.86

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCN
COGT
Founded
1982
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
6.0B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
FCN
COGT
Price
$174.90
$32.86
Analyst Decision
Hold
Strong Buy
Analyst Count
1
15
Target Price
$165.00
$36.21
AVG Volume (30 Days)
492.6K
1.6M
Earning Date
04-23-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
5.51
N/A
EPS
8.24
N/A
Revenue
$3,788,857,000.00
$7,871,000.00
Revenue This Year
$7.39
N/A
Revenue Next Year
$7.10
$1,581.80
P/E Ratio
$20.47
N/A
Revenue Growth
2.44
N/A
52 Week Low
$149.31
$3.72
52 Week High
$183.72
$43.73

Technical Indicators

Market Signals
Indicator
FCN
COGT
Relative Strength Index (RSI) 63.60 35.48
Support Level $174.66 $33.27
Resistance Level $180.44 $41.02
Average True Range (ATR) 4.79 1.79
MACD 1.31 -0.37
Stochastic Oscillator 86.91 11.73

Price Performance

Historical Comparison
FCN
COGT

About FCN FTI Consulting Inc.

FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: